441 related articles for article (PubMed ID: 20664173)
1. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity.
Tam J; Vemuri VK; Liu J; Bátkai S; Mukhopadhyay B; Godlewski G; Osei-Hyiaman D; Ohnuma S; Ambudkar SV; Pickel J; Makriyannis A; Kunos G
J Clin Invest; 2010 Aug; 120(8):2953-66. PubMed ID: 20664173
[TBL] [Abstract][Full Text] [Related]
2. A novel peripheral cannabinoid 1 receptor antagonist, AJ5012, improves metabolic outcomes and suppresses adipose tissue inflammation in obese mice.
Han JH; Shin H; Park JY; Rho JG; Son DH; Kim KW; Seong JK; Yoon SH; Kim W
FASEB J; 2019 Mar; 33(3):4314-4326. PubMed ID: 30566396
[TBL] [Abstract][Full Text] [Related]
3. Role of adiponectin in the metabolic effects of cannabinoid type 1 receptor blockade in mice with diet-induced obesity.
Tam J; Godlewski G; Earley BJ; Zhou L; Jourdan T; Szanda G; Cinar R; Kunos G
Am J Physiol Endocrinol Metab; 2014 Feb; 306(4):E457-68. PubMed ID: 24381003
[TBL] [Abstract][Full Text] [Related]
4. Antagonism of peripheral hepatic cannabinoid receptor-1 improves liver lipid metabolism in mice: evidence from cultured explants.
Jourdan T; Demizieux L; Gresti J; Djaouti L; Gaba L; Vergès B; Degrace P
Hepatology; 2012 Mar; 55(3):790-9. PubMed ID: 21987372
[TBL] [Abstract][Full Text] [Related]
5. Effects of CB1 receptor blockade on monosodium glutamate induced hypometabolic and hypothalamic obesity in rats.
Chen W; Chen Z; Xue N; Zheng Z; Li S; Wang L
Naunyn Schmiedebergs Arch Pharmacol; 2013 Aug; 386(8):721-32. PubMed ID: 23620336
[TBL] [Abstract][Full Text] [Related]
6. CB1 receptor blockade counters age-induced insulin resistance and metabolic dysfunction.
Lipina C; Vaanholt LM; Davidova A; Mitchell SE; Storey-Gordon E; Hambly C; Irving AJ; Speakman JR; Hundal HS
Aging Cell; 2016 Apr; 15(2):325-35. PubMed ID: 26757949
[TBL] [Abstract][Full Text] [Related]
7. A novel peripheral cannabinoid receptor 1 antagonist, BPR0912, reduces weight independently of food intake and modulates thermogenesis.
Hsiao WC; Shia KS; Wang YT; Yeh YN; Chang CP; Lin Y; Chen PH; Wu CH; Chao YS; Hung MS
Diabetes Obes Metab; 2015 May; 17(5):495-504. PubMed ID: 25656402
[TBL] [Abstract][Full Text] [Related]
8. Rimonabant improves metabolic parameters partially attributed to restoration of high voltage-activated Ca2+ channels in skeletal muscle in HFD-fed mice.
Chen B; Hu N
Braz J Med Biol Res; 2017 May; 50(6):e6141. PubMed ID: 28492810
[TBL] [Abstract][Full Text] [Related]
9. Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice.
Patel KN; Joharapurkar AA; Patel V; Kshirsagar SG; Bahekar R; Srivastava BK; Jain MR
Can J Physiol Pharmacol; 2014 Dec; 92(12):975-83. PubMed ID: 25361428
[TBL] [Abstract][Full Text] [Related]
10. CB
Drori A; Gammal A; Azar S; Hinden L; Hadar R; Wesley D; Nemirovski A; Szanda G; Salton M; Tirosh B; Tam J
Elife; 2020 Nov; 9():. PubMed ID: 33210603
[TBL] [Abstract][Full Text] [Related]
11. Neutral antagonism at the cannabinoid 1 receptor: a safer treatment for obesity.
Meye FJ; Trezza V; Vanderschuren LJ; Ramakers GM; Adan RA
Mol Psychiatry; 2013 Dec; 18(12):1294-301. PubMed ID: 23070073
[TBL] [Abstract][Full Text] [Related]
12. A Peripheral CB1R Antagonist Increases Lipolysis, Oxygen Consumption Rate, and Markers of Beiging in 3T3-L1 Adipocytes Similar to RIM, Suggesting that Central Effects Can Be Avoided.
Paszkiewicz RL; Bergman RN; Santos RS; Frank AP; Woolcott OO; Iyer MS; Stefanovski D; Clegg DJ; Kabir M
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32927872
[TBL] [Abstract][Full Text] [Related]
13. Cannabinoid type 1 receptor blockade induces transdifferentiation towards a brown fat phenotype in white adipocytes.
Perwitz N; Wenzel J; Wagner I; Büning J; Drenckhan M; Zarse K; Ristow M; Lilienthal W; Lehnert H; Klein J
Diabetes Obes Metab; 2010 Feb; 12(2):158-66. PubMed ID: 19895638
[TBL] [Abstract][Full Text] [Related]
14. CB(1) antagonism restores hepatic insulin sensitivity without normalization of adiposity in diet-induced obese dogs.
Kim SP; Woolcott OO; Hsu IR; Stefanoski D; Harrison LN; Zheng D; Lottati M; Kolka C; Catalano KJ; Chiu JD; Kabir M; Ionut V; Bergman RN; Richey JM
Am J Physiol Endocrinol Metab; 2012 May; 302(10):E1261-8. PubMed ID: 22374758
[TBL] [Abstract][Full Text] [Related]
15. Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats.
Nogueiras R; Veyrat-Durebex C; Suchanek PM; Klein M; Tschöp J; Caldwell C; Woods SC; Wittmann G; Watanabe M; Liposits Z; Fekete C; Reizes O; Rohner-Jeanrenaud F; Tschöp MH
Diabetes; 2008 Nov; 57(11):2977-91. PubMed ID: 18716045
[TBL] [Abstract][Full Text] [Related]
16. Novel effects of the cannabinoid inverse agonist AM 251 on parameters related to metabolic syndrome in obese Zucker rats.
Merroun I; Sánchez-González C; Martínez R; López-Chaves C; Porres JM; Aranda P; Llopis J; Galisteo M; Zarzuelo A; Errami M; López-Jurado M
Metabolism; 2013 Nov; 62(11):1641-50. PubMed ID: 23932644
[TBL] [Abstract][Full Text] [Related]
17. Targeting the endocannabinoid/CB1 receptor system for treating obesity in Prader-Willi syndrome.
Knani I; Earley BJ; Udi S; Nemirovski A; Hadar R; Gammal A; Cinar R; Hirsch HJ; Pollak Y; Gross I; Eldar-Geva T; Reyes-Capo DP; Han JC; Haqq AM; Gross-Tsur V; Wevrick R; Tam J
Mol Metab; 2016 Dec; 5(12):1187-1199. PubMed ID: 27900261
[TBL] [Abstract][Full Text] [Related]
18. Peripheral reduction of FGFR4 with antisense oligonucleotides increases metabolic rate and lowers adiposity in diet-induced obese mice.
Yu XX; Watts LM; Manchem VP; Chakravarty K; Monia BP; McCaleb ML; Bhanot S
PLoS One; 2013; 8(7):e66923. PubMed ID: 23922646
[TBL] [Abstract][Full Text] [Related]
19. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity.
Ravinet Trillou C; Delgorge C; Menet C; Arnone M; Soubrié P
Int J Obes Relat Metab Disord; 2004 Apr; 28(4):640-8. PubMed ID: 14770190
[TBL] [Abstract][Full Text] [Related]
20. Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats.
Janiak P; Poirier B; Bidouard JP; Cadrouvele C; Pierre F; Gouraud L; Barbosa I; Dedio J; Maffrand JP; Le Fur G; O'Connor S; Herbert JM
Kidney Int; 2007 Dec; 72(11):1345-57. PubMed ID: 17882151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
